China’s early stage Panacea
How Panacea plans to deploy funds to back early stage biotech, medtech in China
Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing and company formation strategy in Chinese life
